Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Indian firm Natco Pharma has signed an agreement with Mabxience, a unit of Swiss-based Chemo Sa Lugano to purchase four mAb drug substances from Chemo and use them to manufacture finished dosage pharmaceutical formulations.
Subscribe to our email newsletter
Three of the four products including Trastuzumab, Bevacizumab, Rituximab belong to the oncology segment, while Etanercept is used to treat auto-immune disease.
As per the terms of the agreement, Natco will manufacture drug products, undertake local clinical trials, file registration of dossiers, to apply for market authorizations and commercialize the product in India and other Asian countries.
Natco expects to complete the mAb initiative in a period of 24 to 36 months.